Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma

NCT06331260 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT06331260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06331260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma
Lead sponsor
Zhejiang University
Phase
Observational
Overall status
Not yet recruiting
Start date
April 1, 2024
Completion date
April 1, 2028
Enrollment
600 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alpha-fetoprotein, hepatocellular carcinoma, liver transplantation, protein induced by vitamin k absence or antagonist-ii